The purpose of this study is to evaluate a combination of three anticancer drugs — irinotecan, temozolomide, and bevacizumab — in patients with neuroblastoma that has returned or is no longer responding to standard therapies.
Irinotecan and temozolomide are two drugs that have been used together to treat neuroblastoma. Bevacizumab is not approved for neuroblastoma, but is used to treat advanced colorectal, lung, breast, kidney, and brain cancers.
Bevacizumab works by blocking vascular endothelial growth factor (VEGF), a protein that promotes the growth of tumor cells and blood vessels in and around tumors. It has been used with irinotecan before to treat cancer, but not in children with neuroblastoma.